Overcome Biochemical Aspirin Resistance Through Cilostazol Combination "ARCC"

Completed

Phase 4 Results

Summary of Purpose

This study will recruit 316 ischemic stroke patients taking aspirin. They will be randomly assigned into cilostazol group or placebo group. Every patients will take 200mg of cilostazol a day or placebo for 1 month. The primary outcome variable of this study is rate of biochemical aspirin resistance on the Ultra Rapid Platelet Function Assay-ASA.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 10 December 2009.

1 Mar 2007 12 Mar 2007 1 Jun 2008 1 Jul 2008 1 Nov 2009 22 Jan 2009
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Purpose: Treatment
  • Endpoint: Safety/Efficacy Study
  • Intervention: Parallel Assignment

Contacts

  • Lee Ju-Hun, MD. 82-2-2224-2695 leejuhun@hallym.or.kr

    sunuck@amc.seoul.kr